{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:48:16Z","timestamp":1766177296549,"version":"3.48.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtocrr.2025.100912","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:43:14Z","timestamp":1758955394000},"page":"100912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC"],"prefix":"10.1016","volume":"6","author":[{"given":"Makoto","family":"Nishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Enatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunoj Chacko","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100912_bib1","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100912_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jtocrr.2025.100912_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100912_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12885-018-4075-5","article-title":"Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"issue":"suppl 4","key":"10.1016\/j.jtocrr.2025.100912_bib8","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11523-024-01094-5","article-title":"Impact of first-line osimertinib and other EGFR-tyrosine kinase inhibitors on overall survival in untreated advanced EGFR-mutated non-small cell lung cancer in Japan: updated data from TREAD Project 01","volume":"19","author":"Hibino","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100912_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib13","article-title":"Distinct progression and efficacy of first-line osimertinib treatment according to mutation subtypes in metastatic NSCLC harboring EGFR mutations","volume":"5","author":"Takeyasu","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100912_bib14","article-title":"The whole picture of first-line osimertinib for EGFR mutation-positive advanced NSCLC: real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa study)","volume":"5","author":"Watanabe","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100912_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.jtocrr.2025.100912_bib16","article-title":"4O First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2025.100912_bib17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100912_bib18","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","article-title":"4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib19","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2024.11.032","article-title":"RELAY: final overall survival for erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC","volume":"20","author":"Nakagawa","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib21","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1111\/cas.14655","article-title":"Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2025.100912_bib22","article-title":"Final survival outcomes with ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC: RELAY Japanese subset","volume":"6","author":"Nishio","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100912_bib23","article-title":"RELAY+: exploratory study of ramucirumab plus gefitinib in untreated patients with EGFR-mutated metastatic NSCLC","volume":"3","author":"Nishio","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100912_bib24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.21037\/tlcr-22-736","article-title":"Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)","volume":"12","author":"Nishio","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100912_bib25","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100912_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-07-2404","article-title":"Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib","volume":"68","author":"Gilmer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100912_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","article-title":"Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis","volume":"72","author":"Sheng","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset","volume":"14","author":"Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2025.100912_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jtocrr.2025.100912_bib31","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","article-title":"Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L)","volume":"23","author":"Haratake","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib32","doi-asserted-by":"crossref","first-page":"S1635","DOI":"10.1016\/j.annonc.2024.10.663","article-title":"630MO first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort","volume":"35","author":"Yang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108496","article-title":"Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset","volume":"204","author":"Cho","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtocrr.2025.100912_bib35","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdr487","article-title":"Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer","volume":"23","author":"Hayashi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/1759-7714.12463","article-title":"Clinical significance of post-progression survival in lung cancer","volume":"8","author":"Imai","year":"2017","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12885-018-4685-y","article-title":"Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non\u2013small cell lung cancer: a meta-analysis","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2025.100912_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijmr.IJMR_1896_17","article-title":"A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients","volume":"150","author":"Thomas","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jtocrr.2025.100912_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40264-021-01127-2","article-title":"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor mutation-positive, metastatic non-small-cell lung cancer: safety profile and manageability","volume":"45","author":"Nadal","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtocrr.2025.100912_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1419256","volume":"14","author":"Fujiwara","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2025.100912_bib43","article-title":"Ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated metastatic EGFR-mutated NSCLC: RELAY Japanese subset","volume":"2","author":"Nishio","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100912_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn J Clin Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:44:42Z","timestamp":1766177082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325001304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666364325001304"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100912","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the International Association for the Study of Lung Cancer\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100912"}}